STRATA Skin Sciences

STRATA Skin Sciences, Inc. is a medical technology company in Dermatology and Plastic Surgery. It engages in developing, commercializing and marketing products for the treatment of dermatologic conditions. The firm operates through the following segments: Dermatology Recurring Procedures and Dermatology Procedures Equipment. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. The Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. The company was founded by Dina Gutkowicz-Krusin in December 1989 and is headquartered in Horsham, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

STRATA Skin Sciences pursues growth through international expansion and profitability

STRATA Skin Sciences is strategically focusing on increasing revenue per device and expanding internationally to drive growth.
While facing challenges in domestic billings and lower revenue, the company's cost-cutting measures are enhancing profitability.
The company's efforts to optimize operations and drive revenue growth position it well for future success.

STRATA Skin Sciences reports revenue growth and operational improvements in Q2 2024

STRATA Skin Sciences (SSKN) delivered a mixed performance in Q2 2024 with revenue growth, improved operational efficiency, and strategic financing.
The company showcased strengths in equipment revenue growth, expanding customer base, and effective cost management strategies.
Challenges remain in achieving profitability, sustaining growth momentum, and managing operational costs effectively.
Opportunities lie in leveraging marketing efforts, expanding product offerings, exploring new markets, and optimizing operational efficiency for future growth.

STRATA Skin Sciences reports solid Q3 performance with growth opportunities

STRATA Skin Sciences demonstrated solid financial performance in Q3 2024, leveraging improved revenue per XTRAC and cost management.
While facing challenges in device adoption and operating expenses, the company's DTC initiatives and cash position present growth opportunities.
By focusing on enhancing device utilization and investing in innovation, STRATA Skin Sciences can drive future revenue growth and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

STRATA Skin Sciences, Inc. (SSKN) Q4 2023 Earnings Call Transcript

Company to host conference call and webcast today, March 27, 2024, at 4:30 PM ET Company to host conference call and webcast today, March 27, 2024, at 4:30 PM ET

STRATA Skin Sciences Reports Fourth Quarter and Full-Year 2023 Earnings

HORSHAM, Pa., March 13, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced it plans to release its fourth quarter and full-year 2023 financial results on Wednesday, March 27, 2024. Management will hold a conference call to review the financial results and provide a corporate update at 4:30 PM ET on the same day.

STRATA Skin Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results on March 27, 2024

HORSHAM, Pa., March 07, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced an initiative aimed at expanding insurance coverage for essential treatments for conditions such as mycosis fungoides, lichen planus, alopecia areata, and cutaneous T-Cell lymphoma (CTCL), with an initial targeted focus on expanding coverage for vitiligo and atopic dermatitis, skin diseases effecting up to 3 and 16 million people in the United States respectively1. The Company is leveraging its extensive patient database and engaging in targeted governmental relations efforts, this initiative focuses on broadening Current Procedural Terminology (“CPT”) code coverage to increase patient access to advanced treatments and enable higher provider reimbursement rates.

STRATA Skin Sciences Announces Initiative to Expand Treatment Coverage

–Amends certain financial covenants to enhance liquidity and financial flexibility–  –Ensures alignment with the Company's current and future business operations–

STRATA Skin Sciences Announces Successful Amendment to Credit Agreement with MidCap Financial

Agreement further solidifies the strength and growth of the partnership between STRATA Skin Sciences and Kosmo Meditech Agreement further solidifies the strength and growth of the partnership between STRATA Skin Sciences and Kosmo Meditech

STRATA Skin Sciences Announces Expansion of Distribution Agreement with Kosmo Meditech

Shmuel Gov Promoted to Chief Operating Officer Dr. Amandeep Kaur Hired as Vice President of Marketing and Business Growth HORSHAM, Pa., Dec. 04, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced the promotion of Shmuel Gov to Chief Operating Officer.

STRATA Skin Science Announces Strengthening of Leadership Team

HORSHAM, Pa., Dec. 01, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced that the company will be participating in the Benchmark 12th Annual Discovery One-on-One Investor Conference being held in New York City on December 7, 2023. Details for the event are as follows:

STRATA Skin Sciences to Participate in the Benchmark 12th Annual Discovery One-on-One Investor Conference

STRATA Skin Sciences, Inc. (NASDAQ:SSKN ) Q3 2023 Earnings Conference Call November 14, 2023 4:30 PM ET Company Participants Rich Cockrell – Investor Relations Dolev Rafaeli – President and Chief Executive Officer Chris Lesovitz – Chief Financial Officer Conference Call Participants Jeffrey Cohen – Ladenburg Thalmann Operator Greetings, and welcome to the STRATA Skin Sciences Third Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode.

STRATA Skin Sciences, Inc. (SSKN) Q3 2023 Earnings Call Transcript

Company to Host Conference Call and Webcast Today, November 14, 2023, at 4:30 PM ET Company to Host Conference Call and Webcast Today, November 14, 2023, at 4:30 PM ET

STRATA Skin Sciences Reports Third Quarter 2023 Revenue

HORSHAM, Pa., Nov. 02, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced it plans to release its third quarter 2023 financial results on Tuesday, November 14, 2023. Management will hold a conference call to review the financial results and provide a corporate update at 4:30 PM ET on the same day.

STRATA Skin Sciences to Report Third Quarter 2023 Financial Results on November 14, 2023

HORSHAM, Pa., Oct. 31, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN) (the “Company”), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced that, as previously reported on its Form 8-K filed on October 30, 2023, effective as of the close of trading on October 31, 2023, the Company granted equity-based awards, in accordance with Nasdaq Listing Rule 5635(c)(4), to Dr. Dolev Rafaeli as an inducement material to Dr. Rafaeli entering into an employment agreement with the Company and commencing employment as its Vice-Chairman, Chief Executive Officer and President. Dr. Rafaeli received an equity-based award of a stock option to purchase 1,754,569 shares of the Company's common stock, with a strike price of $0.53 per share, vesting over a three-year period, with 145,465 options vesting on January 31, 2024, and 145,464 options vesting every three months thereafter, provided in general that Dr. Rafaeli remains in the Company's employ through each applicable vesting date and subject to the terms and conditions of the applicable award agreement.

STRATA Skin Sciences, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

HORSHAM, Pa., Aug. 24, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced it will host a virtual key opinion leader (KOL) event on XTRAC® and TheraClear®X on Wednesday, September 20, 2023, at 10:00 AM – 12:00 PM ET. To register for the event, click here.

STRATA Skin Sciences to Host Virtual KOL Event on XTRAC® and TheraClear®X

STRATA Skin Sciences, Inc. (NASDAQ:SSKN ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Nicole Jones - IR Bob Moccia - CEO Chris Lesovitz - CFO Conference Call Participants Destiny Hance - Ladenburg Thalmann Operator Greetings. Welcome to STRATA Skin Sciences' 2Q 2023 Earnings Conference Call.

STRATA Skin Sciences, Inc. (SSKN) Q2 2023 Earnings Call Transcript

Company to Host Conference Call and Webcast Today, August 9, 2023, at 4:30 PM ET Company to Host Conference Call and Webcast Today, August 9, 2023, at 4:30 PM ET

STRATA Skin Sciences Reports Second Quarter 2023 Revenue

HORSHAM, Pa., Aug. 01, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced that the company will be participating in several conferences during August. Details are found below:

STRATA Skin Sciences to Participate in Upcoming August Conferences

HORSHAM, Pa., July 28, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced that it plans to release its second quarter 2023 financial results on Wednesday, August 9, 2023. Management will hold a conference call to review the financial results and provide a corporate update starting at 4:30 PM ET on the same day.

STRATA Skin Sciences to Report Second Quarter 2023 Financial Results on August 9, 2023

HORSHAM, Pa., July 06, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced that it has completed the refinancing of its existing debt agreement with a new facility from MidCap Financial (MidCap). The new debt facility consists of a refinancing of the existing $8.0 million term loan and an additional $7.0 million tranche funded at closing. The Company also has the option to receive an additional $5 million tranche in 2024.

STRATA Skin Sciences Secures additional $12 Million Financing with MidCap Financial

HORSHAM, Pa., June 30, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced the appointment of Dr. Uri Geiger as the Chairman of the Board of Directors. William Humphries will step down as Chairman and continue to serve on the Board, effective July 3, 2023, as he transitions into his role as Chief Executive Officer of Alcami Corporation.

STRATA Skin Sciences Appoints Dr. Uri Geiger to Chairman of its Board of Directors

Study evaluating efficacy and safety of TheraClearX on mitigating mild to moderate acne in healthy teenagers and young adults Study evaluating efficacy and safety of TheraClearX on mitigating mild to moderate acne in healthy teenagers and young adults

STRATA Skin Sciences Announces First Patients Treated in TheraClear®X Clinical Study for Acne

HORSHAM, Pa., May 19, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced Joel L. Cohen, MD (FAAD, FACMS), Director of AboutSkin Dermatology in Greenwood Village, Colorado will be demonstrating the TheraClear®X device at the Music City Scale Symposium for Cosmetic Advances and Laser Education at the Grand Hyatt in Nashville, Tennessee from May 17-21, 2023.

STRATA Skin Sciences Announces TheraClear®X Product Demonstration at Music City Scale Symposium for Cosmetic Advances and Laser Education

STRATA Skin Sciences, Inc. (NASDAQ:SSKN ) Q1 2023 Results Conference Call May 15, 2023 4:30 PM ET Company Participants Bob Moccia - Chief Executive Officer Chris Lesovitz - Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Operator Greetings. Welcome to the STRATA Skin Sciences First Quarter 2023 Earnings Conference Call.

STRATA Skin Sciences, Inc. (SSKN) Q1 2023 Earnings Call Transcript

Achieved revenue of $7.6 million for the first quarter 2023 Company to host conference call and webcast today, May 15, 2023, at 4:30 PM ET HORSHAM, Pa., May 15, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced financial results for the first quarter ended March 31, 2023.

STRATA Skin Sciences Reports First Quarter 2023 Revenue

HORSHAM, Pa., May 08, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced the company will participate in the Inaugural EF Hutton Global Conference at The Plaza Hotel in New York City from May 10-11, 2023.

STRATA Skin Sciences to Participate in Inaugural EF Hutton Global Conference

HORSHAM, Pa., April 12, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced preliminary revenue for the first quarter of 2023 in the range of $7.3 - $7.8 million and is expected to be the strongest first-quarter results since the first quarter of 2016.

News for STRATA Skin Sciences Stock (SSKN)